65 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
of tobevibart and elebsiran; the ability of tobevibart and elebsiran (as monotherapies or combination therapies) to treat and/or prevent chronic … hepatitis Delta (CHD) or chronic hepatitis B virus (CHB); the Company’s preclinical pipeline; the Company’s collaboration with the Biomedical Advanced
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
a corporate update and reported financial results for the first quarter ended March 31, 2024.
“We are excited to share important data from our Phase 2 chronic … for the company.”
Pipeline Programs
Chronic Hepatitis Delta (CHD)
On March 5, 2024, Vir announced its Phase 2 chronic hepatitis delta SOLSTICE trial completed
8-K
EX-99.1
bwaq6cj6ge4iip j3vl
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
wafm2c8uho aedy
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
EX-99.1
ko2ce9ev cdwpvml1
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
w147427drka2 ehlbx0
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
dpuxzqjokl53r10lzrj0
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
3xc1 2s8yc
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
65ka6iq bs3w
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
1qyemlojobw
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am